Compare Raytheon Technologies Corp (RTX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Sana Biotechnology Inc — how do they compare? Raytheon Technologies Corp trades at $223.28 (market cap $302.06B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.01B). The key difference: Raytheon Technologies Corp is far larger — about 299.1× Sana Biotechnology Inc's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| RTX | SANA | |
|---|---|---|
Market Cap | $302.06B | $1.01B |
Sector | Industrials | Health |
52-Week High | $224.12 | $5.92 |
52-Week Low | $151.75 | $2.68 |
Enterprise Value | $332.61B | $980.22M |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.
SANA Biotechnology trades at $3.52, up 3.23% with a bullish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn improved in 2026. Recent positive developments include clinical data presentations and a $69M stock offering. Analyst consensus remains strong with 82% buy ratings and a $9.50 price target.
While SANA shows promising clinical progress and strong analyst support, significant financial losses and cash burn present substantial risks. The stock's upside potential depends on successful clinical trial outcomes and path to profitability, making it suitable for risk-tolerant investors seeking biotech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
